The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy
- PMID: 34436637
- DOI: 10.1007/s00345-021-03816-0
The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy
Abstract
Background: Race/ethnicity may predispose to less favorable prostate cancer characteristics in intermediate risk prostate cancer (IR PCa) patients. We tested this hypothesis in a subgroup of IR PCa patients treated with radical prostatectomy (RP).
Methods: We relied on the Surveillance, Epidemiology and End Results 2004-2016. The effect of race/ethnicity was tested in univariable and multivariable logistic regression analyses predicting upstaging (pT3+/pN1) and/or upgrading (Gleason Grade Group [GGG] 4-5) at RP.
Results: Of 20,391 IR PCa patients, 15,050 (73.8%) were Caucasian, 2857 (14.0%) African-American, 1632 (8.0%) Hispanic/Latino and 852 (4.2%) Asian. Asian patients exhibited highest age (64 year), highest PSA (6.8 ng/ml) and highest rate of GGG3 (31.9%). African-Americans exhibited the highest percentage of positive cores at biopsy (41.7%) and the highest proportion of NCCN unfavorable risk group membership (54.6%). Conversely, Caucasians exhibited the highest proportion of cT2 stage (35.6%). In univariable analyses, Hispanic/Latinos exhibited the highest rates of upstaging/upgrading among all race/ethnicities, in both favorable and unfavorable groups, followed by Asians, Caucasians and African-Americans in that order. In multivariable analyses, Hispanic/Latino race/ethnicity represented an independent predictor of higher upstaging and/or upgrading in favorable IR PCa (odds ratio [OR] 1.27, p < 0.01), while African-American race/ethnicity represented an independent predictor of lower upstaging and/or upgrading in unfavorable IR PCa (OR 0.79, p < 0.001).
Conclusion: Race/ethnicity predisposes to differences in clinical, as well as in pathological characteristics in IR PCa patients. Specifically, even after full statistical adjustment, Hispanic/Latinos are at higher and African-Americans are at lower risk of upstaging and/or upgrading.
Keywords: African-American; Asian; Hispanic/Latino; PCa; SEER.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients.Prostate. 2022 May;82(6):687-694. doi: 10.1002/pros.24313. Epub 2022 Feb 21. Prostate. 2022. PMID: 35188982
-
Tumor upgrading among very favorable intermediate-risk prostate cancer patients treated with robot-assisted radical prostatectomy: how can it impact the clinical course?Int Urol Nephrol. 2024 Aug;56(8):2597-2605. doi: 10.1007/s11255-024-04019-3. Epub 2024 Mar 30. Int Urol Nephrol. 2024. PMID: 38553619
-
Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics.Eur Urol. 2015 Mar;67(3):451-7. doi: 10.1016/j.eururo.2014.03.026. Epub 2014 Apr 5. Eur Urol. 2015. PMID: 24746973
-
No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance.World J Urol. 2021 Jul;39(7):2499-2506. doi: 10.1007/s00345-020-03485-5. Epub 2020 Oct 13. World J Urol. 2021. PMID: 33048258 Free PMC article.
-
Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review.Prostate Cancer Prostatic Dis. 2017 Jun;20(2):127-136. doi: 10.1038/pcan.2016.56. Epub 2017 Apr 18. Prostate Cancer Prostatic Dis. 2017. PMID: 28417980 Review.
Cited by
-
Diagnosis of Clinically Significant Prostate Cancer Diagnosis Without Histological Proof in the Prostate-specific Membrane Antigen Era: The Jury Is Still Out.Eur Urol Open Sci. 2022 Oct 1;45:50-51. doi: 10.1016/j.euros.2022.08.024. eCollection 2022 Nov. Eur Urol Open Sci. 2022. PMID: 36199620 Free PMC article. No abstract available.
-
External Tertiary-Care-Hospital Validation of the Epidemiological SEER-Based Nomogram Predicting Downgrading in High-Risk Prostate Cancer Patients Treated with Radical Prostatectomy.Diagnostics (Basel). 2023 May 3;13(9):1614. doi: 10.3390/diagnostics13091614. Diagnostics (Basel). 2023. PMID: 37175005 Free PMC article.
-
Influence of Biopsy Gleason Score on the Risk of Lymph Node Invasion in Patients With Intermediate-Risk Prostate Cancer Undergoing Radical Prostatectomy.Front Surg. 2021 Dec 9;8:759070. doi: 10.3389/fsurg.2021.759070. eCollection 2021. Front Surg. 2021. PMID: 34957202 Free PMC article.
-
Sex differences resulted differential morbidity and mortality in bladder cancer: smoke, hormone or urobiome?World J Urol. 2022 May;40(5):1245-1246. doi: 10.1007/s00345-021-03775-6. Epub 2021 Jul 1. World J Urol. 2022. PMID: 34196757 No abstract available.
-
Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer-a multicenter SEARCH cohort study.Prostate Cancer Prostatic Dis. 2024 Aug 12. doi: 10.1038/s41391-024-00880-6. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39134653
References
-
- Fletcher SA, von Landenberg N, Cole AP et al (2020) Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer Prostatic Dis 23:81–87 - DOI
-
- Reese AC, Pierorazio PM, Han M et al (2012) Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology 80:1075–1079 - DOI
-
- Serrano NA, Anscher MS (2016) Favorable vs unfavorable intermediate-risk prostate cancer: a review of the new classification system and its impact on treatment recommendations. Oncology 30:229–236 - PubMed
-
- Kane CJ, Eggener SE, Shindel AW et al (2017) Variability in outcomes for patients with intermediate-risk prostate cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2–3) and implications for risk stratification: a systematic review. Eur Urol Focus 3:487–497 - DOI
-
- Preisser F, Cooperberg MR, Crook J et al (2020) Intermediate-risk prostate cancer: stratification and management. Eur Urol Oncol 3:270–280 - DOI
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous